Published • loading... • Updated
Trump administration to announce drug pricing deals
The agreements build on earlier deals with 17 major drugmakers and could save up to $64.3 billion over 10 years, officials said.
- On Monday, President Donald Trump is expected to announce a new round of drug-pricing agreements as part of a push to make healthcare more affordable for Americans.
- These new deals build on agreements the administration reached last year with 17 of the world's largest drugmakers, including Pfizer, Eli Lilly, and Amgen, to lower prescription costs.
- Germany-Based Bayer, Japan's Takeda, and Australia-based CSL are expected to join the initiative, following reports that smaller mid-size firms previously delayed signing due to limited financial benefits.
- Officials state the broader effort could save $64.3 billion in federal and state spending over the next decade, though they characterize this projection as speculative.
- Ahead of midterm elections that will decide control of Congress, the White House is promoting these healthcare efforts while Trump continues pressuring manufacturers to lower prices.
Insights by Ground AI
7 Articles
7 Articles
Coverage Details
Total News Sources7
Leaning Left1Leaning Right1Center5Last UpdatedBias Distribution72% Center
Bias Distribution
- 72% of the sources are Center
72% Center
14%
C 72%
14%
Factuality
To view factuality data please Upgrade to Premium
